Chay Ngee Lim, PhD

Pfizer Inc

Poster(s):

• PI-110 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE
  Wednesday, May 28, 2025

  5:00 PM - 6:30 PM East Coast USA Time